Study of bortezomib plus CPX-351 for newly diagnosed TP53-mutated AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of two drugs (bortezomib and CPX-351) for people newly diagnosed with a specific type of AML that has a TP53 gene change. The goal is to see if this combination is safe and works better than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a new diagnosis of acute myeloid leukemia (AML) with a TP53 mutation
- You have not received any chemotherapy (except hydroxyurea) for your AML
- You are in good enough health to do daily activities (Karnofsky score 70% or higher)
- Your heart, liver, and kidneys are working well enough as shown by tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
This trial tests a new drug (axatilimab) combined with two standard chemotherapy drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has a TP53 mutation. The goal is to see if this combination helps control the cancer better than current treatments.
This study tests whether CPX-351 can work better than standard intensive chemotherapy in adults with newly diagnosed AML that fits specific genetic patterns. It aims to improve how long patients stay in control of the leukemia.
This trial adds an experimental drug called bleximenib to the usual chemotherapy for people newly diagnosed with AML who have certain genetic changes (NPM1 or KMT2A). The goal is to see if adding this drug helps the treatment work better.
This trial tests a new drug, rezatapopt, combined with azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. It is only for people whose cancer cells have a specific change in a gene called TP53 (the Y220C mutation). The goal is to see if this combination can help control the disease.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.